Relapsed or refractory neuroblastoma is uniformly fatal. We hypothesized that allogeneic response could provide a platform for immunotherapy in neuroblastoma. We therefore undertook a pilot trial of unrelated cord blood transplantation after reduced intensity conditioning regimen (RIC) in children with relapsed neuroblastoma to assess engraftment and tolerability in this heavily pretreated population. The RIC included CY (50 mg/kg, day À6), fludarabine (40 mg/m 2 , days À6 to À2), total body irradiation (200 cGy, day À1), and rabbit antithymocyte globulin (2.5 mg/kg, days À3 to À1). Six patients were enrolled: four were in partial responsive relapse, one with a mixed response and one in refractory relapse. All patients tolerated the regimen well and had donor engraftment with full neutrophil and plt recovery (median time 12 and 35 days, respectively). One patient never experienced neutropenia and another did not need plt transfusions. All patients progressed after transplant (median time 55 days, 26-180 days). Natural killer (NK) cell counts were normal within 2 months, whereas T-cell recovery was slower. In conclusion, unrelated cord blood engrafts after RIC in children with refractory neuroblastoma. Future research should be aimed at transplanting patients with minimal residual disease, using less intensive immunosuppression and adding NK-cell based post transplant immunotherapy.
Introduction
The outcome of children with relapsed or refractory neuroblastoma is uniformly fatal in spite of the intensive chemo-radiation therapy. Alternative therapeutic approaches including immunotherapy are being explored. Allogeneic hematopoietic transplantation is associated with a graft-vs-tumor (GVT) effect, which adds to the antitumor effect of the preparative regimen. This GVT effect has been shown in patients with refractory solid tumors. 1 The early trials of matched sibling allogeneic BMT in children with neuroblastoma between 1985 and 1995 reported outcomes similar to those of autologous transplantation. 2, 3 Given a higher rate of TRM with allogeneic hematopoietic SCT and the occurrence of GVHD, autologous is the preferred therapeutic option for those in need of hematopoietic SCT: only 25 allogeneic transplantations were therefore performed for neuroblastoma in Europe in 2006. [4] [5] [6] [7] [8] [9] However, progress has been made in allogeneic transplantation both from a better understanding of immunogenicity and decreased transplant toxicity. First, it has been shown that the GVT effect of allogeneic transplantation may be enhanced by several therapeutic modalities: rapid immunosuppression withdrawal, donor lymphocyte infusion, 10, 11 natural killer (NK) cell alloreactivity, 9,12 minor histocompatiblity Ag targeting. 13 IL-2, IL-7, IL-15, GM-CSF and IFN-a are being examined to enhance this GVT effect. [14] [15] [16] [17] Allogeneic hematopoietic transplantation thus appears to be not only an immunotherapeutic modality, but also as a platform for subsequent immunotherapy. 1, 11, 18 Second, reduced-intensity conditioning regimen (RIC) followed by PBSCT has been shown to induce rapid donor chimerism in adult patients with solid tumors, thereby providing a GVT effect without the toxicity of a myeloablative preparative regimen. 1 Third, partially HLA-mismatched unrelated cord blood transplantation (UCBT) has been shown in childhood hematological malignancies to have outcomes similar to those of HLAmatched BMT. [19] [20] [21] [22] [23] Furthermore, it has been shown to retain a GVL effect in spite of a lower risk of GVHD. [19] [20] [21] [22] [23] Importantly, we showed that an UCB unit can be found within 1 month for 99% of the children in need of a transplant without any risk or constraint for the donor. 23 On the basis of these findings, we hypothesized that HLA-partially mismatched UCBT after RIC could be used as a platform for subsequent immunotherapy. Although it has been shown that a RIC regimen may lead to UCB engraftment in childhood leukemia, 24 some reports suggest that engraftment may be poor in patients with other diseases. [25] [26] [27] Only one previous patient with a solid tumor was reported to engraft successfully after RIC regimen and UCBT. 28 The objective of this pilot trial was therefore to examine engraftment after RIC of partially matched UCB in children with relapsed or refractory neuroblastoma.
Patients and methods

Patient eligibility
Patients aged 18 years or younger with a diagnosis of recurrent or refractory metastatic neuroblastoma were eligible for inclusion in the Solicord trial. Before enrollment, patients were treated with chemotherapy to achieve the best disease control possible before transplant at treating physician's discretion. A single UCB unit with at least 4/6 HLA-compatibility (AB and B loci defined by serological methods, and DRB1 allele by high-resolution molecular typing), and at least 3.7 Â 10 7 nucleated cells/kg of recipient weight was required. Patients were required to have a Lansky or Karnofsky performance score X50, life expectancy X8 weeks and absence of active infection and normal organ function (total bilirubin p1.5 Â the upper limit of normal range, SGPT (ALT) o5 upper limit of normal range, serum albumin 420 g/L, serum creatinine p1.5 upper limit of normal range or, if abnormal serum creatinine, radioisotope glomerular filtration rate X70 mL/ min per 1.73 m 2 , ejection fraction X30% in echocardiography, no supplemental oxygen requirement, DLCO X30%, FVC/TLC X30%, FEV1 X30%). Patients with a previous allogeneic transplant were not eligible. Patients must have recovered from the acute toxic effect of chemotherapy, immunotherapy or radiotherapy before entering the trial (minimum of 6 months after autologous transplant, 6 weeks after BU or nitrosoureas, 3 weeks after other cytotoxic chemotherapy, and 7 days after treatment with a biologic agent). Pre-transplant status of the disease was assessed according to the International Neuroblastoma Response Criteria. The study was approved by the Institutional Review Boards and Ethics Committees of Centre Hospitalier Universitaire Sainte-Justine and Methodist Hospital, San Antonio. All patients or legal guardians provided written informed consent before entry into this study, as requested by local regulations.
Treatment
The preparative regimen was CY (a single dose of 50 mg/kg i.v. on day À6), fludarabine (40 mg/m 2 i.v. once daily on days À6 to À2, for five doses), TBI (a single dose of 200 cGy on day À1), and rabbit anti-thymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA, USA, 2.5 mg/kg i.v. once daily on days À3 to À1, for three doses).
Post transplant GVHD prophylaxis was cyclosporine i.v. or p.o. from day À3 to day þ 180 targeting for a trough blood level between 200 and 300 mg/L, and mycophenolate mofetil 15 mg/kg i.v. or p.o twice daily from day À3 to day þ 30. Filgrastim (5 mg/kg/day s.c.) was given, from the first day the total WBC count fell below 2.5 Â 10 9 /L until the neutrophil count was over 2.5 Â 10 9 /L for 2 consecutive days. In case of evidence of recurrent disease, rapid discontinuation of cyclosporine was recommended.
Assessment of trial endpoints
Sustained donor engraftment was the primary endpoint of the trial. Sustained donor engraftment was defined as neutrophil recovery (X0.5 Â 10 9 /L) with complete donor chimerism before day þ 45. Chimerism was assessed by quantitative PCR of STR by LabCorp (San Antonio, TX, USA) for San Antonio patients or using a technique we described elsewhere for Montreal patients. 29 The sensitivity of these chimerism assays was ± 5%. Complete donor chimerism was defined as 490% cells of donor origin in blood.
Hematopoietic recovery was assessed by several secondary endpoints. Primary donor engraftment was defined as neutrophil recovery with complete donor chimerism on day þ 30 or before. As the patients received a RIC regimen, it was expected that some of the patients would not experience severe neutropenia or thrombocytopenia. The number of patients having maintained a neutrophil count 40.5 Â 10 9 /L was thus assessed. Time to neutrophil recovery (first of 3 consecutive days with a neutrophil count 40.5 Â 10 9 /L) was assessed for the remaining patients. Similarly, the number of patients having maintained their plt count 420 Â 10 9 /L was assessed. Time to plt recovery (first of 3 consecutive days with a plt count 420 Â 10 9 /L without plt transfusion 7 days before) was assessed for the remaining patients. NK cell and T-cell reconstitution was assessed by lymphocyte counts and flow cytometry using CD56 and CD3 on peripheral blood cells. Initial NK cell and T-cell counts were planned to be performed at 1 month post transplant.
Acute GVHD was analyzed based on Glucksberg staging of skin, gastrointestinal or liver disease. 30 Chronic GVHD was defined by the occurrence of symptoms in any organ system fulfilling the criteria of chronic GVHD. 31 Infections were recorded and described. Treatment-related mortality was defined as death without evidence of tumor recurrence. Progression-free survival was defined as survival without progressive disease.
Analysis and stopping rules
This feasibility trial planned to enroll 10 patients. Stopping rules were in place for TRM (three or more transplantrelated deaths among the first seven patients), and prolonged neutropenia (three or more patients without neutrophil recovery at day þ 30 among the first seven patients). Table 1 . All patients had recurrent or refractory neuroblastoma. Median age was 8.5 years. All patients were transplanted with active disease: four were in partial response, one in mixed response and one in refractory relapse. Five patients had undergone previous autologous transplantation 29-43 months before enrollment. None of the patients received previous immunotherapy. Two patients had experienced one relapse, two had experienced two relapses and one three relapses. Lansky performance status at transplant was X90%. All patients received the planned preparative regimen and GVHD prophylaxis. Cyclosporine was stopped for one patient because of the occurrence of post transplant lymphoproliferative disease.
Results
Patient characteristics
All patients received a single UCB unit. The degree of HLA compatibility was 6/6 for one patient, 5/6 for three patients and 4/6 for two patients. Median total nucleated cell dose before cryopreservation was 6.9 Â 10 7 /kg. Median total nucleated cell dose infused (after thaw) was 6.5 Â 10 7 /kg. Median CD34 þ cell dose measured in the UCB unit before cryopreservation was 3.0 Â 10 5 /kg.
Primary endpoint: sustained donor engraftment Five patients were evaluable. All five experienced sustained donor engraftment (the primary endpoint of this study) with donor chimerism 490% before day þ 45. One patient was not evaluable because of death on day þ 30 from progressive disease. He had neutrophil recovery on day þ 12, with 41% donor chimerism on day þ 19. There were no instances of secondary graft rejection.
Hematopoietic and immune recovery and primary donor engraftment Hematopoietic recovery is described in Table 2 . One patient maintained his neutrophil count over 0.5 Â 10 9 /L throughout the process. For the others, the median time to neutrophil recovery was 12 days (5-26 days). Similarly one patient maintained a plt count over 20 Â 10 9 /L. For the rest the median time to plt recovery was 35 days. All five alive patients had plt recovery before day þ 45.
Four patients had NK cell and T-cell counts performed before day þ 45 (Table 2) . For these four patients, this early NK cell count was within the normal range (148-700 Â 10 6 /L), whereas the T-cell count was low (0-190 Â 10 6 /L). One patient died before any NK and T-cell counts were made. One patient had these initial counts performed on day þ 66 and both of them were within the normal range.
Primary donor engraftment was defined as neutrophil recovery with complete donor chimerism at day þ 30. On day þ 30, four out of five alive patients had 490% donor cells in blood and the remaining one had 490% donor cells in blood on day þ 32.
Toxicity
The transplant regimen was well tolerated in this heavily pretreated cohort of children. There were no toxic deaths. None of the patients developed acute or chronic GVHD. Three of the six patients had infections post transplant (Pseudomonas aeruginosa bacteremia, parainfluenza 2 virus upper respiratory tract infection and tonsillar infectious mononucleosis-like post transplant lymphoproliferative disease with EBV viremia successfully managed by immunosuppression withdrawal). One of these patients showed evidence of CMV reactivation and was treated with gancyclovir. Apart from hematologic and infectious toxicity, no patient had CTC grade 3 or greater toxicity.
Disease progression and survival
All patients had disease progression after transplant. Median time to disease progression was 55 days (day þ 26 to day þ 180). At time of progression, immunosuppression was rapidly tapered or stopped without any evidence of disease control or GVHD. Disease progression was the cause of death for all patients. Median survival was 124 days (1-28 months post transplant).
Discussion
In this patient population, RIC was immunosuppressive enough to allow engraftment of partially mismatched UCB. The regimen was well tolerated in this cohort of heavily pretreated children. These young children were transplanted with single large cell dose units and engraftment Cord blood transplantation for childhood neuroblastoma C Jubert et al was rapid. The lack of GVHD and rejection suggest that immunosuppression could be attenuated in future studies.
There was no evidence of an allogeneic graft-vsneuroblastoma effect of UCBT in this trial. GVT effect in solid tumors is typically delayed for months after transplant. 1 Given the rapidity of tumor recurrence in our patients, there was not time to establish T-cell mediated GVT activity. Future clinical trails based on this approach should be aimed at transplanting patients in minimal residual disease. Indeed, transplanting patients with low minimal residual disease has been shown to be the best approach to take advantage of post transplant allogenicity. 11, 32 Furthermore, the immunosuppressive prophylactic regimen was intensive, as exemplified by the absence of GVHD and the occurrence of a post transplant lymphoproliferative disease in one patient. We choose to use rabbit antithymocyte globulin in the conditioning regimen to maximize the NK cell GVT effect. Indeed, neuroblastoma cells express low levels or no HLA class I potentially making them excellent targets for NK cells, 9, 33 and we have shown that rabbit anti-thymocyte globulin enhances IFN-production by NK cells. 34 However, our data suggest that the profound T-cell depletion induced by rabbit anti-thymocyte globulin should also be taken into account, and its use in future trials is questionable. 35 Finally, additional post transplant immunotherapy should be considered in future trials based on this combined RIC-UCBT approach.
11 Donor lymphocyte infusion is unavailable after UCBT, but several other modalities are under investigation to increase the GVT effect of allogeneic transplantation, as NK cell activation, 9,12 minor histocompatiblity Ag targeting 13 and the use of cytokines such as IL-2, IL-7, IL-15, GM-CSF and IFN-a. [14] [15] [16] [17] In this model, we observed that NK cell recovered earlier than T-cell counts. This is in line with our observation of a more rapid NK cell reconstitution after UCBT when compared with BMT. 36 NK cell counts recovered before disease progression in all but one patient. Taken together, all these data suggest that future post transplant immunotherapy based on this RIC-UCBT approach should target donor NK cells rather than T cells.
All our patients had been heavily pretreated before transplantation and our engraftment rate may therefore not be applicable to patients having received less chemotherapy before transplantation. Indeed, it has been shown that UCB may not engraft after RIC in chemotherapy-naive patients. [25] [26] [27] However, it is expected that the patients enrolled in future trials will have received intensive chemotherapy before transplantation. First, this salvage approach is aimed at patients refractory to former chemotherapy. Second, transplanting patients with minimal residual disease will need to use additional chemotherapy in the immediate pre-transplant period.
In conclusion, UCB engrafts after RIC in children with refractory neuroblastoma. However, in patients with high tumor burden relapse was rapid and there was not enough time to establish a GVT effect. Further research will focus on patients with minimal residual disease, will use of less immunosuppressive GVHD prophylaxis regimen and will 
Conflict of interest
The authors declare no conflict of interest.
